Scopus İndeksli Yayınlar Koleksiyonu
Permanent URI for this collectionhttps://hdl.handle.net/11727/4809
Browse
3 results
Search Results
Item Severe hypocalcemia and hypercalciuria due to contrast medium in the course of acute myocardial infarction(2016) Coner, Ali; Genctoy, Gultekin; Balcioglu, Serhat; Muderrisoglu, Haldun; 0000-0002-5711-8873; 0000-0002-5145-2280; 0000-0002-9635-6313; 27389156; ABD-7321-2021; AAJ-5551-2021; AAG-8233-2020Item Successful treatment of massive pulmonary embolism with reteplase(2018) Coner, Ali; Cicek, Davran; Balcioglu, Serhat; Akinci, Sinan; Müderrisoglu, Haldun; 0000-0002-9635-6313; 0000-0001-5250-5404; 0000-0002-5711-8873; 29512616; AAC-8036-2020; AAG-8233-2020; AAD-5564-2021; ABD-7321-2021Unexpected and unexplained out-of-hospital cardiac arrests have a poor prognosis. Difficulties encountered during the differential diagnosis phase may delay the administration of specific treatment for treatable and reversible causes of cardiac arrest. Massive pulmonary embolism is a reversible cause of cardiac arrest, but without proper management it has a high mortality rate. Presently described is the case of a 53-year-old female patient with a massive pulmonary embolism.Item Mid-term clinical outcomes of new generation drug-eluting stents for treatment of diffuse coronary artery disease(2018) Coner, Ali; Cicek, Davran; Akinci, Sinan; Balcioglu, Serhat; Altin, Cihan; Muderrisoglu, Haldun; 30516523Objective: Diffuse coronary artery disease (CAD) is a challenging issue in clinical cardiology practice. There are limited data about percutaneous revascularization in these patients. Methods: This study was an observational clinical evaluation. The records of patients with diffuse CAD revascularized with new-generation drug-eluting stents (DES) were researched retrospectively. Patients treated with multiple, overlapping new-generation DES (at least 60mm in length per vessel) were included. The incidence of major adverse cardiac events (MACE), defined as cardiac death, stent thrombosis, non-fatal myocardial infarction, and target lesion revascularization (TLR), at the end of the first year following the index procedure was recorded. Results: A total of 71 patients (with 75 coronary vessels) treated with new-generation DES for diffuse CAD were enrolled in the study. Zotarolimus-eluting stents were used in 48 vessels and biolimus A9-eluting stents were used in 27 vessels. The median total stent length per vessel was 75.0 mm (60.0-106.0) and the median number of stents implanted was 3 (2-4) for each vessel. The cumulative incidence of MACE at the end of the first year was 11.2% (8 patients). The presence of diabetes mellitus (DM) and ST-segment elevated myocardial infarction (STEMI) were defined as independent clinical risk factors related to MACE development. Conclusion: Coronary artery revascularization with new-generation drug-eluting stents can be a good choice in the treatment of selected patients with diffuse CAD. DM and STEMI were found to be related to poorer clinical outcomes with this treatment option in our study.